Mendelian randomization demonstrated a causal protective association between SGLT2 inhibition and reduced risk of liver fibrosis/cirrhosis, while in vivo experiments revealed that EMP attenuates hepatic steatosis and liver injury, improves redox balance, and suppresses inflammatory and fibrotic responses. This evidence concerns the gene SLC5A2 and fatty liver disease.